Hims & Hers stock has been surging since May, but has its valuation gotten too rich?Healthcare stocks don't have to be making weight loss drugs to be hot buys due to the rising demand for glucagon-like peptide 1 (GLP-1) treatments. A good example of that is Hims & Hers Health (HIMS -12.85%). Up more than 140% this year, the telehealth company has been a hot buy with investors not only for its impressive growth but also for its ability to help connect patients with GLP-1 drugs.However, the company's strategy ...